News | News By Subject | News by Disease News By Date | Search News

Muscular Dystrophy News Articles

Get Our FREE
Industry eNewsletter
email:    
Top Breaking News
Catabasis (CATB) Plunges on DMD Drug Trial Failure     2/1/2017
JPM17: Sarepta (SRPT)'s New Numbers Impress Investors, Stock Gained $300 Million Overnight     1/11/2017
Humana (HUM) to Cover Sarepta (SRPT)'s Controversial DMD Drug But There's a Catch     10/27/2016
Sarepta (SRPT) Gets No Love From the FDA's New Drugs Director     10/21/2016
PTC Therapeutics (PTCT) Tanks After the FDA Denies DMD Drug Translarna Again     10/17/2016
Watch Out, Ionis Pharma (IONS): Could This Little Biotech’s Experimental SMA Treatment Be a Threat?     10/17/2016
Sarepta (SRPT) Goes for a New DMD Combo With New $562 Million+ Deal With Summit Therapeutics     10/4/2016
Saga Continues for Sarepta (SRPT) as FDA Head Calls for Retraction of 'Misleading' 2013 Study     9/23/2016
Victory at Last! Sarepta (SRPT) Stock Doubles as the FDA Finally Approves DMD Drug     9/20/2016
Turn the Page: Sarepta (SRPT) Stock Pops on Rumors DMD Drug Naysayer Leaves the FDA     9/15/2016
Sarepta (SRPT)’s Duchene Muscular Dystrophy Drug: Evaluating the Placebo Effect     8/19/2016
Sarepta (SRPT) Stock Surges After Government Website Indicates Firm is Recruiting for Phase III Study     8/5/2016
FDA Hits DMD Drugmaker Santhera (SANN.SW) With Lengthy Delay     7/14/2016
This Year’s Top 10 Disappointing Clinical Trials—So Far!     7/6/2016
Sarepta (SRPT)'s Study Period Extension May Help Gain DMD Drug Approval in the Long Run     6/24/2016

News from Around the Web
PTC Therapeutics (PTCT) Wants a Slice of Sarepta (SRPT)'s DMD Pie, Says Rejected Drug May Help Some Patients     10/7/2016
After Sarepta (SRPT)'s Win, BioMarin (BMRN) Wants a Piece of the Action Too     9/23/2016
Approving A Muscular Dystrophy Drug Exposes A Civil War At The FDA     9/20/2016
Approving Sarepta (SRPT)'s DMD Drug Could Force FDA To Get Creative     5/26/2016
Robotic Arm For Duchenne Patients Developed, University of Twente Reveals     1/25/2016
"Ringo The Dog" Helps Find Potential New Therapy For Muscular Dystrophy     11/18/2015
Scientists Make Diseased Cells Synthesize Their Own Drug, The Scripps Research Institute Reveals     9/4/2014
Viagra And Cialis Could Help Treat Duchenne Muscular Dystrophy, Cedars--Sinai Heart Institute Study     5/8/2014
What The Delay Of A Promising Muscular Dystrophy Drug Means For Patients, Investors And All Of Biotech     11/13/2013
Double Gene Flaws Lead to Rare Muscular Dystrophy, University of Rochester and Fred Hutchinson Cancer Research Center Study     11/14/2012
New Muscular Dystrophy Treatment Offers Hope, North Shore-Long Island Jewish Research Institute Study     3/24/2011
Human Protein Improves Muscle Function of Muscular Dystrophy in Mice, Brown University Study     12/28/2010
Viagra May Help Heart Effects of Muscular Dystrophy, University of Washington and University of North Carolina Study Finds     10/19/2010
Tarantula Venom Used in Research for Muscular Dystrophy, University at Buffalo Study     10/5/2010
Add to Human Genome's Greatest Hits: DNA Culprits That Cause FSH Muscular Dystrophy Found, Leiden University Medical Center and University of Rochester Study     8/23/2010

Press Releases
Capricor Therapeutics, Inc. Terminates Natriuretic Peptide Program Deal With The Mayo Clinic     2/17/2017
Catabasis (CATB) Release: Company's Phase I Data On Edasalonexent (CAT-1004), A Potential Disease-Modifying Therapy Being Developed For Duchenne Muscular Dystrophy, Published In The Journal Of Clinical Pharmacology     1/19/2017
Catabasis (CATB) Release: Positive Preclinical Research On The Edasalonexent (CAT-1004) Program, A Potential Disease-Modifying Therapy For Duchenne Muscular Dystrophy, Published In JCI Insight     1/4/2017
Eli Lilly (LLY) Joins cTAP, Helping To Accelerate Enriched Clinical Trial Design For The Provision Of New Treatments For Duchenne Muscular Dystrophy Patients     12/21/2016
Sarepta (SRPT) Announces EMA Validation Of Eteplirsen Authorization Application For Treatment Of Duchenne Muscular Dystrophy Amenable To Exon Skipping 51     12/20/2016
Months Later, Sarepta (SRPT)'s Controversial DMD Drug is Still Making Waves     12/14/2016
Catabasis (CATB) Provides Edasalonexent And Rare Disease Pipeline Updates At Investor Day     11/17/2016
PTC Therapeutics (PTCT) Rockets as DMD Drug Wins Extended European Approval     11/11/2016
Capricor Therapeutics, Inc. Announces Plans To Expand Clinical Development Program In Duchenne Muscular Dystrophy To Evaluate Peripheral And Respiratory Muscle Function     11/11/2016
cTAP Announces Two Research Publications Categorizing And Predicting Disease Progression In Duchenne Muscular Dystrophy     10/31/2016
CureDuchenne Release: Non-Profits, Pharmaceutical Companies And Noted Clinicians Collaborate To Launch The Collaborative Trajectory Analysis Project (Ctap); Advancing Clinical Trial Design For Duchenne Muscular Dystrophy     10/25/2016
Catabasis (CATB) Presents Positive Data From Part A Of The MoveDMD Trial Of Edasalonexent (CAT-1004), A Potential Disease-Modifying Therapy For DMD, At The World Muscle Society Congress     10/6/2016
Catabasis (CATB) Completes Target Enrollment For Part B Of The MoveDMD Trial, A Phase II Trial Of Edasalonexent (CAT-1004) For The Potential Treatment Of Duchenne Muscular Dystrophy     10/4/2016
Sarepta (SRPT) Announces First Patient Dosed In Phase III Clinical Trial Of SRP-4045 And SRP-4053 For The Treatment Of Duchenne Muscular Dystrophy Amenable To Exon 45 Or 53 Skipping     9/29/2016
Catabasis (CATB) And Sarepta (SRPT) Announce A Joint Research Collaboration In Duchenne Muscular Dystrophy     9/29/2016

//-->